Novo Nordisk A/S reported second-quarter 2025 sales of $11.68 billion, missing the consensus of $11.79 billion. Sales increased by 13% in Danish kroner and 18% at CER, with GLP-1 diabetes sales up 8% and Obesity care sales up 53%. Insulin sales increased by 5% and Rare disease sales by 28%.

The weight loss drug maker reported earnings of 91 cents per share, missing the consensus of 93 cents. Ozempic sales increased 15% to 31.79 billion Danish kroner, while Wegovy sales jumped 75% to 19.53 billion Danish kroner.

Novo Nordisk shared its trimmed 2025 outlook, with sales growth of 8-14% at CER and operating profit growth of 10-16% at CER. The lowered outlook is due to lower growth expectations in the second half, compounded GLP-1 use, slower market expansion, and competition.

Novo Nordisk announced plans to launch Ozempic in the cash-pay channel and stated that Wegovy’s penetration in the cash channel is around 10% of total U.S. prescriptions. The company terminated development of a once-weekly GLP-1/GIP co-agonist for weight management.

Novo Nordisk has terminated development of INV-347 and zalfermin for portfolio considerations. The company faces a federal securities class action lawsuit for cutting its sales and profit outlook, with allegations of misleading shareholders about market potential.

Novo Nordisk has filed numerous lawsuits against organizations involved in illegal activities related to unsafe non-FDA-approved compounded semaglutide. The company has obtained 44 permanent injunctions to stop the illegal marketing of knockoff Wegovy and Ozempic.

Courts have issued 44 permanent injunctions against defendants in similar cases, deterring unlawful conduct and ordering defendants to forfeit profits. NVO stock is trading lower by 2.24% premarket at $46.16.

Read more at Yahoo Finance: Compounded GLP-1s And Competition Force Novo Nordisk To Slash Outlook